Drug Type Small molecule drug |
Synonyms Remo-M, Remozen-M |
Target |
Action activators, inhibitors |
Mechanism PRKAB1 activators(Protein kinase AMP-activated non-catalytic subunit beta 1 activators), SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date India (18 Aug 2019), |
Regulation- |
Molecular FormulaC4H11N5 |
InChIKeyXZWYZXLIPXDOLR-UHFFFAOYSA-N |
CAS Registry657-24-9 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 2 | India | 18 Aug 2019 |